Hertraz 440 mg Injection

Hertraz 440 mg Injection Specification

Dosage Form
Lyophilized Powder for Injection

Indication
Breast cancer, Metastatic gastric cancer

Salt Composition
Trastuzumab (440mg)

Enzyme Types
Not an enzyme (Monoclonal antibody)

Feature
Recombinant humanized monoclonal antibody targeting HER2 receptor

Ingredients
Trastuzumab, excipients and sterile water for injection (as solvent)

Application
Other

Ph Level
As per company norms

Physical Color/Texture
White to pale yellow lyophilized powder

Fermentation Smell
Normal Smell

Storage Instructions
Dry place

Shelf Life
upto 24 Months

Contraindications
Hypersensitivity to trastuzumab or any excipients

Method of Preparation
Reconstitute with provided solvent before use

Usage Precaution
Monitor cardiac function during therapy

Suitable For
Adult patients

Pack Size
1 vial + 1 solvent ampoule

Target Receptor
HER2/neu receptor

Dispensing Condition
To be administered by healthcare professional only

Regulatory Approval
DCGI approved

Administration Route
Intravenous infusion

Prescription Status
Prescription only

Solvent Provided
Yes, sterile water for injection included

Packaging Type
Box pack with vial and ampoule

Strength
440 mg per vial

Hertraz 440 mg Injection Trade Information

Minimum Order Quantity
1 Unit

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Units Per Month

Delivery Time
7-10 Seconds

Main Export Market(s)
Asia, Australia, North America, Eastern Europe, Western Europe

Main Domestic Market
All India

About Hertraz 440 mg Injection

Hertraz 440 mg Injection delivers prodigious value and is now available at a special rate. Harness the heroic power of Trastuzumab, a recombinant humanized monoclonal antibody, targeting the HER2/neu receptor in breast and metastatic gastric cancer. This expertly prepared box pack includes 1 vial and a solvent ampoule, ensuring an enlightened and safe reconstitution process. Add to Cart with confidence, knowing it is DCGI approved and prescribed exclusively for adults. The injection is designed for intravenous use and must be administered by healthcare professionals only. Storage is simple-keep it in a dry place and use within 24 months.

Hertraz 440 mg Injection: Areas of Application & Key Features

Hertraz 440 mg Injection is specially indicated for adjuvant and metastatic breast cancer, as well as metastatic gastric cancer. Its major application areas lie in targeting HER2/neu receptors, providing patients with advanced therapy options. Key features include recombinant monoclonal antibody formulation, easy reconstitution with supplied sterile water, and suitability for adult patients. The injection comes as a white to pale yellow lyophilized powder, ensuring precise dosage. Each pack includes a vial and solvent ampoule, offering exceptional reliability.

Hertraz 440 mg: Market Availability & Packaging Insights

Hertraz 440 mg Injection is in stock ready for immediate dispatch, meeting significant demands across the main domestic market in India. Each unit is packaged securely-one vial and one solvent ampoule per box. Sample policy is flexible; you may request a sample before deciding the final asking price or estimate for bulk orders. The packaging ensures safety and maintains the product's shelf life and quality, giving confidence to both wholesalers and exporters.

Specification

Directions for Use	For I.V Infusion,Multiple Use Vial
Form	Injection
Packaging Size	1 Vial of Trastuzumab,2 Vial Of BWFI
Prescription/Non prescription	Prescription
Packaging	Vial
Treatment	Adjuvant breast cancer,Metastatic breast cancer,Metastatic gastric cancer.
Manufacturer	Mylan
Composition	Trastuzumab
Brand	Hertraz 440

FAQ's of Hertraz 440 mg Injection:

Q: How should Hertraz 440 mg Injection be prepared and administered?

A: Hertraz 440 mg Injection must be reconstituted with the supplied sterile water for injection before intravenous infusion. Administration should be done by a qualified healthcare professional, following all recommended guidelines for dosage and infusion rate.

Q: What is the main indication for using Hertraz 440 mg Injection?

A: The injection is primarily indicated for adult patients with breast cancer (adjuvant and metastatic) and metastatic gastric cancer where HER2/neu receptor expression is confirmed.

Q: When should cardiac function be monitored during Hertraz therapy?

A: Cardiac function should be closely monitored before starting, during, and after Hertraz therapy, as there can be cardiac-related risks associated with Trastuzumab treatment.

Q: Where should Hertraz 440 mg Injection be stored?

A: Store Hertraz 440 mg Injection in a dry place, away from direct sunlight, adhering to company norms and keeping it under recommended temperature conditions to preserve efficacy.

Q: What are the benefits of choosing Hertraz 440 over alternatives?

A: Hertraz 440 mg Injection provides a DCGI-approved, quality-assured treatment with a prodigious safety and reliability profile, and a value-based price point, making it a trusted solution in cancer therapy.

Q: What precautions should be observed before starting treatment with Hertraz?

A: Before initiating therapy with Hertraz, ensure the patient does not have hypersensitivity to Trastuzumab or its excipients, and assess baseline cardiac function due to possible adverse cardiac effects.